NRG1 and myeloid sarcoma: In those models where NRG1 expressions are dysregulated, exogenous administration of NRG1 or enhancement of its signaling has been shown to restore remyelination potential and improve axonal ensheathment, suggesting a therapeutic avenue for diseases such as MS (Table 2) [211,212].